306 related articles for article (PubMed ID: 33140049)
1. Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture.
Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
bioRxiv; 2020 Nov; ():. PubMed ID: 33140049
[TBL] [Abstract][Full Text] [Related]
2. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
[TBL] [Abstract][Full Text] [Related]
3. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y; Wang J
bioRxiv; 2020 Jan; ():. PubMed ID: 32511378
[TBL] [Abstract][Full Text] [Related]
4. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y; Wang J
Cell Res; 2020 Aug; 30(8):678-692. PubMed ID: 32541865
[TBL] [Abstract][Full Text] [Related]
5. Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir.
Xia Z; Sacco M; Hu Y; Ma C; Meng X; Zhang F; Szeto T; Xiang Y; Chen Y; Wang J
ACS Pharmacol Transl Sci; 2021 Aug; 4(4):1408-1421. PubMed ID: 34414360
[TBL] [Abstract][Full Text] [Related]
6. Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M
Sacco MD; Ma C; Lagarias P; Gao A; Townsend JA; Meng X; Dube P; Zhang X; Hu Y; Kitamura N; Hurst B; Tarbet B; Marty MT; Kolocouris A; Xiang Y; Chen Y; Wang J
bioRxiv; 2020 Jul; ():. PubMed ID: 32766590
[TBL] [Abstract][Full Text] [Related]
7. Cytopathic Effect Assay and Plaque Assay to Evaluate
Hu Y; Ma C; Wang J
Bio Protoc; 2022 Feb; 12(3):e4314. PubMed ID: 35284599
[TBL] [Abstract][Full Text] [Related]
8. Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions.
Wang Y; Li P; Lavrijsen M; Li Y; Ma Z; Peppelenbosch MP; Baig MS; Pan Q
Arch Virol; 2022 Apr; 167(4):1125-1130. PubMed ID: 35171357
[TBL] [Abstract][Full Text] [Related]
9. Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell.
Hu Y; Jo H; DeGrado WF; Wang J
J Med Virol; 2022 May; 94(5):2188-2200. PubMed ID: 35080027
[TBL] [Abstract][Full Text] [Related]
10. Current Strategies of Antiviral Drug Discovery for COVID-19.
Mei M; Tan X
Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
[TBL] [Abstract][Full Text] [Related]
11. Investigating theobromine as a potential anti-human coronaviral agent.
Li J; Wang Y; Rajpoot S; Lavrijsen M; Pan Q; Li P; Baig MS
Microbiol Immunol; 2023 Sep; 67(9):404-412. PubMed ID: 37415325
[TBL] [Abstract][Full Text] [Related]
12. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies.
Tan B; Joyce R; Tan H; Hu Y; Wang J
Acc Chem Res; 2023 Jan; 56(2):157-168. PubMed ID: 36580641
[TBL] [Abstract][Full Text] [Related]
14. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses.
Wang R; Zhai G; Zhu G; Wang M; Gong X; Zhang W; Ge G; Chen H; Chen L
Bioorg Chem; 2023 Jan; 130():106264. PubMed ID: 36395603
[TBL] [Abstract][Full Text] [Related]
15. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of
Tong X; Keung W; Arnold LD; Stevens LJ; Pruijssers AJ; Kook S; Lopatin U; Denison M; Kwong AD
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0084023. PubMed ID: 37800975
[TBL] [Abstract][Full Text] [Related]
17. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M
Sacco MD; Ma C; Lagarias P; Gao A; Townsend JA; Meng X; Dube P; Zhang X; Hu Y; Kitamura N; Hurst B; Tarbet B; Marty MT; Kolocouris A; Xiang Y; Chen Y; Wang J
Sci Adv; 2020 Dec; 6(50):. PubMed ID: 33158912
[TBL] [Abstract][Full Text] [Related]
18. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
Joseph J; Karthika T; Das VRA; Raj VS
Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
[TBL] [Abstract][Full Text] [Related]
19. High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses.
Shen L; Niu J; Wang C; Huang B; Wang W; Zhu N; Deng Y; Wang H; Ye F; Cen S; Tan W
J Virol; 2019 Jun; 93(12):. PubMed ID: 30918074
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1.
Xie X; Lan Q; Zhao J; Zhang S; Liu L; Zhang Y; Xu W; Shao M; Peng J; Xia S; Zhu Y; Zhang K; Zhang X; Zhang R; Li J; Dai W; Ge Z; Hu S; Yu C; Wang J; Ma D; Zheng M; Yang H; Xiao G; Rao Z; Lu L; Zhang L; Bai F; Zhao Y; Jiang S; Liu H
Signal Transduct Target Ther; 2024 Mar; 9(1):54. PubMed ID: 38443334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
